MilliporeSigma scales up lipid production for COVID-19 vaccines

By The Science Advisory Board staff writers

May 26, 2021 -- MilliporeSigma announced that it has launched a new high-purity synthetic cholesterol product to meet demand for lipids, a component of messenger RNA (mRNA)-based vaccines and therapeutics such as those used for COVID-19.

The launch of this new product follows the company's acquisition of AmpTec, a Hamburg, Germany-based mRNA contract development and manufacturing organization.

The company in February announced the extension of its strategic partnership with BioNTech to accelerate the supply of lipids and increase quantities to be delivered toward the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech COVID-19 vaccine.

Filling of MilliporeSigma
Filling of MilliporeSigma's new synthetic cholesterol product at the company's Darmstadt, Germany facility. Image courtesy of MilliporeSigma.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here